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Introduction
Congenital thrombophilia, in general agreement with the 
literature, in addition to its established role in the pathogen-
esis of venous thromboembolism (VTE) increases the risk 
of gestational vascular complications and adverse pregnancy 
outcomes. The role of congenital thrombophilia in gesta-
tional vascular disorders and adverse pregnancy outcomes 
(miscarriage, fetal loss, preeclampsia, intrauterine growth 
restriction and premature abruption of the normally posi-
tioned placenta) has been evaluated in several studies and 
the results are inhomogeneous and contradictory [1-3]. The 
evaluation of a large number of studies in the literature on 
congenital thrombophilia in pregnancy does not assign an 
overall incidence of risk, indicating only an absolutely low 
risk in pregnant women and in the fetus during pregnancy. 
It is still difficult to establish the exact quantitative data of the 
risk for certain adverse events in the presence of these muta-
tions [4, 5]. In addition, the size of estimated risks varies, due 
to the heterogeneity of different study designs [6].
Major forms of hereditary thrombophilia, currently rec-
ognized as independent risk factors for VTE, include pro-
coagulant abnormalities – factor V Leiden G1691A (FVL) 
gene mutation of homozygous or heterozygous type, homo-
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Abstract 
Background: Multiple studies have found a relatively increased risk of placenta-mediated pregnancy complications in women with congenital 
thrombophilia, especially early recurrent pregnancy loss, fetal loss, early-onset preeclampsia, intrauterine growth restriction, and premature abruption 
of normally positioned placenta. However, the extent of the association and the absolute risk are very modest, but they significantly increase in pregnant 
women with severe obstetric complications.
Conclusions: There is convincing evidence that deficiency of natural anticoagulants (antithrombin, protein C, protein S) is a risk factor for late fetal 
loss. Factor V Leiden G1691A gene mutation and prothrombin G20210A gene mutation are associated with a double risk for early and unexplained 
recurrent pregnancy loss and for non-recurrent late fetal loss. The association of congenital thrombophilia with preeclampsia is much more uncertain, 
being probably limited factor V Leiden G1691A gene mutation and more severe cases of preeclampsia. Fewer data are available on intrauterine growth 
restriction (IUGR) and premature abruption of the normally positioned placenta. There is insufficient evidence to suggest an association of other forms of 
congenital thrombophilia with adverse pregnancy outcomes. In addition, genetic and epidemiological research suggests that placenta-mediated pregnancy 
complications are of polygenic multifactorial etiology, with a risk determined by the interaction of multiple genetic variants and other risk factors.
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zygous or heterozygous prothrombin G20210A gene muta-
tion, endogenous deficiency of natural anticoagulants – an-
tithrombin (AT), protein C and protein S, and mutation of 
the methylenetetrahydrofolate reductase (MTHFR) С677Т 
gene. The most common forms of congenital thrombophilia 
are the FVL G1691A gene mutation and the prothrombin 
G20210A gene mutation of the heterozygous type, the other 
types of congenital thrombophilia (AT deficiency, protein C 
and protein S deficiency) have a higher thrombogenic po-
tential, but are less common [ 4, 7-10].
The data below summarize the prevalence of the most 
important types of congenital thrombophilia, including re-
cently detected, a brief review of the available evidence for 
each congenital thrombophilia in relation to adverse preg-
nancy outcomes and the risk of VTE.
FVL g1691A gene mutation. The risk of developing 
VTE increases 2-7 times in people with heterozygous FVL 
G1691A gene mutation and 40-80 times in people with ho-
mozygous FVL G1691A gene mutation [7]. About 40-44% of 
women with VTE, in pregnancy or postpartum, are carriers 
of the FVL G1691A gene mutation and most are heterozy-
gous [4, 11].
Data on the relationship between the FVL G1691A gene 
mutation and fetal loss are inconsistent. In general, the FVL 
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G1691A gene mutation contributes to a small increase in the 
risk of miscarriage and recurrent pregnancy loss (RPL) [1, 
7, 12, 13]. In terms of other parameters of obstetric mor-
bidity, a recent meta-analysis suggests that there is a signifi-
cant increase in the frequency of obstetric complications in 
general, prenatal mortality (stillbirth), severe preeclampsia, 
intrauterine growth restriction (IUGR), newborns small for 
gestational age and premature abruption of the normally po-
sitioned placenta (PANPP) in carriers of the FVL G1691A 
gene mutation [7, 12].
Two recent and comprehensive literature reviews, which 
included prospective, retrospective case-control and cohort 
studies with a moderate heterogeneity, established that car-
riers of the FVL G1691A gene mutation had a relatively high 
risk of RPL (1.52- 2.02 times higher). However, the absolute 
risk of pregnancy loss in women with the FVL G1691A gene 
mutation is low (4.2%) [14].
There is no significant association between the FVL 
G1691A gene mutation and preeclampsia, between the FVL 
G1691A gene mutation and IUGR or newborns small for 
gestational age [14]. The association between PANPP and 
the FVL G1691A gene mutation is also insufficient [8].
However, the association with severe preeclampsia of the 
FVL G1691A gene mutation was assessed in a meta-analysis 
of case-control studies and found a strong association; the 
Odds Ratio (OR) ranges from 2.04 to 3.0 [13]. A systematic 
literature review and a recent meta-analysis, estimating 42 
case-control and cohort studies, published in 2016, found 
a significant association of the FVL G1691A gene mutation 
with newborns small for gestational age (OR 1.40) and the 
lack of association of the FVL G1691A gene mutation with 
premature birth [15].
Prothrombin g20210A gene mutation. The risk of VTE 
in carriers of prothrombin G20210A gene mutation is 2-5 
times higher, and in combination with the FVL G1691A 
gene mutation – 20 times higher [7]. The heterozygous type 
of prothrombin G20210A gene mutation has a 3-8-fold 
higher risk, and the homozygous type – 18-80-fold higher 
risk of thromboembolic events [9].
A systematic literature review found an OR of 2.49 for 
early pregnancy loss, 2.7 for early RPL, 2.66 for late preg-
nancy loss, 2.54 for preeclampsia, 2.92 in newborns small 
for gestational age and 7.71 for PANPP in pregnant women 
with the prothrombin G20210A gene mutation, compared 
to pregnant women who do not have this form of congenital 
thrombophilia [13].
Data cumulated from several studies indicate a signifi-
cant association between the prothrombin G20210A gene 
mutation and RPL, total and severe preeclampsia. Although 
the relationship between the prothrombin G20210A gene 
mutation and VTE during pregnancy is clear, the results of 
some studies do not confirm the impact of this mutation on 
obstetric complications: early RPL, preeclampsia, including 
early or severe onset preeclampsia, PANPP, IUGR, and new-
borns small for gestational age [1, 7, 8, 12, 14].
Protein C deficiency. In general, studies have not found 
a clear association between protein C deficiency and RPL 
[1, 4, 7], but in the case of the association of protein S and 
protein C deficiency, there is a correlation with an increased 
incidence of stillbirth [4]. There are no studies that have 
found an association between protein C deficiency and early 
pregnancy loss, IUGR or PANPP. Protein C deficiency has 
been associated with an increased risk of miscarriage in the 
second trimester, preeclampsia, and stillbirth [8].
Protein S deficiency. A literature review, published in 
2002, evaluating 3-5 relevant studies, found an increased risk 
of preeclampsia (12.7 times higher) with an absolute risk of 
12.3% and an increase in stillbirths (16.2 times higher) with 
an absolute risk of 6% in pregnant women with protein S 
deficiency. There are no studies that have found an associa-
tion between protein S deficiency and early pregnancy loss, 
IUGR or PANPP [8].
Given the low prevalence and limited data, definitive 
conclusions on the effect of protein C and protein S on RPL 
and other pregnancy complications cannot be reached and 
further investigations are needed [1, 3].
AT deficiency was the first hereditary thrombophilia 
identified, which significantly increases the risk of VTE. Be-
ing the most thrombogenic, it has the highest risk of VTE 
among hereditary thrombophilias and often requires long-
term anticoagulant therapy. The lifetime VTE risk accounts 
for 70-90%, being particularly high in pregnancy, postpar-
tum period and after major surgery [7].
Data on the role of AT deficiency in fetal loss (RPL, late 
loss) are contradictory. Some studies have found that women 
with AT-III deficiency have an increased risk of embryonic 
death and fetal death compared to the general population [7, 
8]. The results obtained in other studies suggest an associa-
tion between AT deficiency and pregnancy loss, but the de-
finitive causal relationship is not yet established. AT-III de-
ficiency is rarely associated with severe preeclampsia, IUGR 
or PANPP, but this could be «false negative» due to the low 
prevalence of this form of thrombophilia [7].
MTHFR C677T gene mutation. Hyperhomocystein-
emia is an independent risk factor for VTE. Although sev-
eral studies have not found a firm relationship between the 
homozygous MTHFR C677T gene mutation or elevated ho-
mocysteine levels with adverse pregnancy outcomes [1, 7], a 
recent meta-analysis revealed an association of the MTHFR 
C677T gene mutation with severe preeclampsia [12].
Another meta-analysis, which included 26 case-control 
studies with 2120 cases and 2949 controls (1997-2005), and 
some recent studies found that the MTHFR C677T gene 
mutation is a genetic risk factor of unexplained RPL (two 
or more consecutive miscarriages) only in the Chinese and 
Iranian population, but not in the population of European 
countries [16, 17].
Two recent meta-analyses, which included 27 and 37 
studies (1997-2011 and 1997-2012) with 2427 and 3559 
cases, 2120 and 5097 controls (published in 2012 and 2013), 
identified a significant association between the MTHFR 
C677T gene mutation and unexplained RPL (two or three 
and more consecutive pregnancy losses) in the East Asian 
subgroup (Chinese, Japanese and Korean population) and in 
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the mixed subgroup (Indian, Brazilian, Bahraini, Mexican 
and Egyptian population), but not in the Caucasian popu-
lation, including the population of European origin. In ad-
dition, the study found a genetic heterogeneity between the 
ethnic groups [18, 19].
Three recent meta-analyses, published in 2014 and 2015, 
which included a substantial number of cases and controls, 
revealed statistically significant results of the relationship 
between the MTHFR C677T gene mutation and hyperten-
sion in the population, hypertension in pregnancy and pre-
eclampsia, in particular among Asians and Caucasians. The 
authors consider that this polymorphism is an independent 
risk factor for hypertension and preeclampsia [20, 21].
The results of the Hordaland Homocysteine Study, 
conducted among 5883 women aged 40-42, with 14492 
pregnancies, and published in 2004, revealed that mater-
nal polymorphism MTHFR C677T is associated with in-
creased pregnancy complications in general, increased risk 
of PANPP and, possibly with IUGR or newborns small for 
gestational age [22].
Therefore, all types of congenital thrombophilia are as-
sociated with an increased risk of VTE during pregnancy. 
Several studies confirmed the increased risk of obstetric 
complications in pregnant women with congenital throm-
bophilia, but despite the increased relative risk, the absolute 
risk of VTE and negative pregnancy outcomes is reduced. 
Moreover, the risk estimation largely depends on the type 
of hereditary thrombophilia analyzed, the methodological 
criteria applied for patient selection, the ethnic groups in-
cluded in the study, the differences in sensitivity and speci-
ficity of laboratory methods of thrombophilia detection and 
the polygenic multifactorial etiology of pregnancy complica-
tions.
There is convincing evidence that deficiency of natu-
ral anticoagulants (AT, protein C, protein S) is a risk factor 
for late fetal loss. The FVL G1691A gene mutation and the 
prothrombin G20210A gene mutation are associated with 
a double risk for unexplained early RPL and non-recurrent 
late fetal loss. The association of congenital thrombophilia 
with preeclampsia is much more uncertain, being probably 
limited to the mutation of the FVL G1691A gene and more 
severe cases of preeclampsia.  Fewer data are available about 
IUGR and PANPP. The absolute risk of VTE and negative 
pregnancy outcomes increase significantly in case of a com-
bination of two or more forms of hereditary thrombophilia.
Contemporary technologies have recently contributed 
to the discovery of new forms of hereditary thrombophilia: 
factor V A4070G gene mutation, factor XIII G103T gene 
mutation, MTHFR A1298C gene mutation, methionine syn-
thase (MTR) A2756G gene mutation, methionine synthase 
reductase (MTR) A66G gene mutation, plasminogen acti-
vator inhibitor (PAI-1) gene mutation, cystathionine beta-
synthetase (CBS) 844ins68pb gene mutation. However, in-
formation on these polymorphisms is limited, and their role 
in the development of unexplained RPL and other obstetric 
complications is still controversial [23, 24].
The factor V A4070g gene mutation has a pathologi-
cal role, causing a moderate resistance to activated protein C 
and interacting with the FVL G1691A gene mutation to pro-
duce a more resistant phenotype to activated protein C. As 
no significant increase in the prevalence was identified, the 
presence of the factor V A4070G gene mutation is unlikely 
to be an independent risk factor for pregnancy-associated 
complications. It is controversial whether this mutation is 
associated with an increased thrombotic risk in the absence 
of the FVL G1691A gene mutation [9, 25].
The heterozygous MTHFR A1298C gene mutation has 
a strong association and is a genetic risk factor for RPL [17, 
26] and PANPP [27]. The association of RPL with MTHFR 
A1298C polymorphism is found in previously published 
studies and in a meta-analysis of 5 studies, published in 2013 
[26, 28].
However, recent meta-analyses and case-control stud-
ies did not identify any association between the MTHFR 
A1298C gene mutation and unexplained RPL (two or three 
and more consecutive pregnancy losses) [18, 29, 30], pre-
eclampsia [20], IUGR or newborns small for gestational age 
[22]. In contrast, this mutation may have a protective effect 
by raising serum folic acid levels and decreasing homocyste-
ine levels in the serum [31, 32], and may significantly reduce 
the risk of pregnancy complications in asymptomatic nul-
liparous pregnant women associated with MTHFR C677T 
polymorphism [33], although these results require confir-
mation.
The CBS 844ins68 gene mutation is not a genetic risk 
factor for venous thrombosis [34], although the results of 
some studies suggest possible effects of this polymorphism 
on the risk of idiopathic miscarriage, but it does not have a 
significant certainty [35]. 
MTR A2756g gene mutation. The role of the MTR 
A2756G gene polymorphism in the development of hyper-
homocysteinemia is still controversial. Some studies did not 
find any significant risk of hyperhomocysteinemia in people 
with the MTR A2756G gene mutation. The effect of reducing 
homocysteine levels is synergistic in people with both muta-
tions (CBS 844ins68 gene mutation and MTR A2756G gene 
mutation), and homocysteine levels are much lower than in 
people with one of these polymorphisms [36]. Other studies 
have shown that the MTR A2756G polymorphism indepen-
dently increases the risk of hyperhomocysteinemia [31, 32].
The methionine synthase-reductase gene mutation 
(MTRR A66g) does not affect folic acid levels or the inci-
dence of folate deficiency, has no effect on plasma concentra-
tion of total homocysteine, folate or vitamin B12 in pregnant 
women [37] or the Chinese population [31, 32]. However, 
some studies have shown that the MTRR A66G gene poly-
morphism and folic acid deficiency have been significantly 
associated with high serum levels of total homocysteine [38].
The interactions between gene polymorphisms regulat-
ing folic acid metabolism and homocysteine have signifi-
cant interactive effects leading to a dramatic increase in the 
risk of folate deficiency with the rise of serum homocyste-
ine concentration. Furthermore, patients with two or more 
risk genotypes (MTHFR C677T, MTHFR A1298C, MTR 
A2756G, MTRR A66G gene mutations) have higher folate 
deficiency rates, especially those with the combination of 
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MTHFR C677T and MTRR A66G, between MTHFR C677T 
and MTHFR A1298C or all four risk genotypes [31, 32].
glycoprotein IIb / IIIa mutation. Although informa-
tion on the role of glycoprotein IIb / IIIa mutation in the 
development of pregnancy complications is limited, some 
studies have found a significant association of glycoprotein 
IIIa gene mutation with RPL [28], and PLA2 gene polymor-
phism is associated with miscarriage between the 10th and 
the 20th week of pregnancy [9].
β-fibrinogen gene g455A mutation. Elevated fibrino-
gen levels are associated with an increased risk (4-fold high-
er) of developing VTE, possibly through increased blood 
viscosity and platelet aggregation [7, 9]. The relationship 
between β-fibrinogen G-455A polymorphism and RPL is 
controversial. Some studies have found a significant associa-
tion of β-fibrinogen gene G-455A mutation with RPL and 
may predict an increased risk of repeated pregnancy loss [28, 
39]. However, a recent meta-analysis, published in 2015, did 
not reveal any statistically significant association between 
β-fibrinogen G-455A polymorphism and RPL, including af-
ter the separate analysis of the Asian and Caucasian popula-
tion [40].
PAI-1 gene mutation. A recent, comprehensive up-to-
date meta-analysis, which examined a total of 3561 cases and 
5693 controls, revealed a statistically significant correlation 
of PAI-1 4G/5G gene polymorphism with VTE in the gen-
eral population. This association does not depend on ethnic-
ity – the increased risk of VTE has been found in Asians and 
Caucasians, especially in people with the association of other 
genetic thrombophilic disorders [41].
A recent systematic analysis and meta-analysis, pub-
lished in 2015, which included 18 case-control studies (con-
ducted in 12 countries between 2003 and 2014) with a total 
of 3684 cases and 2208 controls, found a significant asso-
ciation between PAI-1 4G/5G polymorphism and RPL risk 
(two or more consecutive pregnancy losses in the first two 
trimesters). However, there was a statistically significant het-
erogeneity between the included studies [42].
Another recent meta-analysis, published in 2015, which 
included 22 case-control and cohort studies (2003–2014) 
with a total of 4306 cases and 3076 controls, also found a 
significant association between PAI-1 4G/5G polymorphism 
and RPL risk. The race-based analysis found that PAI-1 
4G/5G polymorphism was significantly associated with an 
increased risk of RPL in Caucasians (OR=2.23; 95% CI 1.44-
3.46; P = 0.0003) and no significant association was identified 
in Asians (OR=1.47; 95% CI 0.84-2.59; P = 0.18) [43].
However, several prospective case-control and cohort 
studies did not find any positive association of PAI-1 4G/5G 
polymorphism (isolated or in combination with other forms 
of congenital thrombophilia) with an increased risk of RPL 
and other adverse effects of pregnancy, although in most 
studies the small sample size limits the interpretation of 
these results [44-47].
Factor xIII V34L gene mutation. The association of 
V34L polymorphism of coagulation factor XIII with an in-
creased risk of RPL is still debatable and controversial. Ac-
cording to the results of case-control studies, the factor XIII 
V34L gene mutation of heterozygous type and, to a lesser ex-
tent, of homozygous type, is significantly associated with un-
explained RPL and can be considered a risk factor for RPL, 
being associated with the early development of RPL [48]. A 
recent meta-analysis, published in 2015, also demonstrated 
a close association of the factor XIII V34L gene mutation 
with RPL [40].
However, some studies have not found any association of 
the factor XIII V34L mutation (isolated or in combination 
with other forms of congenital thrombophilia) with RPL. 
However, the small sample size and the inclusion in studies 
of different ethnic groups limited the interpretation of the 
results [45, 49].
Therefore, discrepancies in the relationship between 
different forms of hereditary thrombophilia and placenta-
mediated pregnancy complications can be explained by the 
small sample size, the difference between the ethnic groups, 
and the geographical variation of different cohort studies. 
Large case-control, prospective, and population-based stud-
ies are needed to confirm or to disprove the association of 
more recently discovered hereditary thrombophilia with ad-
verse pregnancy outcomes.
The success achieved in the last decades in the field of 
molecular medicine, biology and medical genetics has con-
tributed to the evaluation from fundamentally new perspec-
tives of the pathogenesis of many obstetric complications, 
which increase fetal, infant and maternal mortality. RPL or 
recurrent miscarriage, pregnancy stopped in evolution, pre-
mature birth, intrauterine fetal death, PANPP, IUGR, severe 
preeclampsia, eclampsia, thromboembolism are still very 
current problems for modern obstetrics. The discovery of 
different forms of acquired and hereditary thrombophilia 
elucidated much more widely the pathogenesis of multiple 
diseases, including in general obstetrics [7, 50].
Although the contribution of congenital thrombophilia 
to negative pregnancy outcomes is controversial, a number 
of complications (fetal loss, preeclampsia, PANPP, IUGR) 
have been associated with congenital thrombophilia [51]. 
The association between pregnancy complications and dif-
ferent forms of congenital thrombophilia, both quantitative-
ly and qualitatively, is briefly described below.
Recurrent miscarriage. The term miscarriage is often 
used to define pregnancy loss from conception to 20 weeks 
of gestation. Subsequently, the loss of pregnancy is called the 
death of the fetus or stillbirth. Early pregnancy loss is de-
fined as the lack of fetal cardiac activity up to 12 weeks of 
gestation, and late pregnancy loss – the lack of fetal cardiac 
activity after 12 weeks of gestation [52, 53].
Common definitions of RPL, also known as repeated 
miscarriage, include the following: 1) two or more miscar-
riages in the first trimester (up to 12 weeks of gestation), 
documented by ultrasound or histopathological examina-
tion, 2) three or more consecutive pregnancy losses up to 
10–12 weeks of gestation, which are not necessarily intra-
uterine [1, 50, 54].
The hemostatic system plays an important role in the 
normal development and success of pregnancy, the implan-
tation process, the invasion and normal development of the 
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trophoblast and placentation. The implantation of the fer-
tilized egg in the decidua establishes a contact between the 
fetus, the placenta and the maternal circulation which is cru-
cial for the pregnancy success. Prothrombotic changes and 
thrombosis can interfere with these processes, contributing 
to severe consequences, including miscarriage, and may ac-
count for many unexplained cases of previous RPL [3, 13, 
52, 53].
While the role of acquired thrombophilia has been ac-
cepted as an etiological factor for RPL, the contribution 
of specific inherited thrombophilic gene polymorphisms 
is controversial. About 52% of pregnant women with se-
vere obstetric complications (severe preeclampsia, IUGR, 
PANPP, stillbirth) had at least one of the three main throm-
bophilic mutations (FVL G1691A gene mutation, prothrom-
bin G20210A gene mutation, and MTHFR C677T gene mu-
tation) [55]. Among women with congenital thrombophilia 
(FVL G1691A gene mutation, protein C deficiency, protein 
S deficiency, AT deficiency, combined defects), fetal loss was 
found in 29.4% of cases [56].
A group of thrombogenic gene mutations, especially dif-
ferent combinations thereof: FVL G1691A, factor V H1299R 
(R2), factor II prothrombin G20210A, factor XIII V34L, 
β-fibrinogen G-455A, PAI-1 4G/5G, glycopropein IIIa L33P, 
MTHFR C677T and MTHFR A1298C can identify people at 
risk of RPL. Individual examination revealed that 3 of these 
mutations (PAI-1 4G / 5G, p = 0.009; factor XIII V34L, p 
<0.0001 and homozygous MTHFR C667T, p=0.0001) cor-
related statistically significantly with RPL, compared to the 
control group. The other 6 mutant genes, cumulatively, also 
correlated statistically significantly with RPL (p <0.0001) 
[57].
Several studies (retrospective, prospective, case-control, 
cohort, cross-sectional, clinical) and contemporary meta-
analyses found no association or found a very weak associa-
tion with an absolutely very low risk between different forms 
of congenital thrombophilia or their combinations and RPL 
[1, 7, 11, 12, 14]. The most recent and well-designed system-
atic review and meta-analysis of the association of congeni-
tal thrombophilia and placenta-mediated pregnancy com-
plications revealed an absolutely increased, but small, and 
statistically significant risk of late RPL in women with the 
FVL G1691A gene mutation [14].
A growing body of evidence (meta-analyses, cross-sec-
tional studies, case-control studies) suggests a significant 
association of late pregnancy loss and unexplained early 
RPL with various types of congenital thrombophilia (FVL 
G1691A gene mutation, prothrombin G20210A gene muta-
tion, MTHFR C677T gene mutation, MTHFR A1298C gene 
mutation, β-fibrinogen G-455A gene mutation, protein C 
deficiency, protein S deficiency). Robust evidence for such 
an association shows the FVL G1691A gene mutation, the 
prothrombin G20210A gene mutation and hyperhomocys-
teinemia [1, 3, 7, 9, 11, 12, 58-61].
In three systematic analyses and meta-analyses, which 
included case-control studies, prospective cohort studies, 
cross-sectional and randomized controlled trials, only the 
heterozygous FVL G1691A gene mutation was associated 
with early and late RPL and late non-recurrent fetal loss, the 
heterozygous prothrombin G20210A gene mutation – with 
early RPL and late non-recurrent fetal loss, and protein S 
deficiency – with RPL and late non-recurrent fetal loss. Pro-
tein C deficiency and AT deficiency have not been associated 
with fetal loss [13, 62, 63].
A systematic literature review with 16 case-control stud-
ies for analysis of FVL G1691A gene mutation and 7 case-
control studies for analysis of prothrombin G20210A gene 
mutation, which defined RPL as two or more pregnancy 
losses in the first or second trimester of pregnancy, found a 
double risk of RPL in women with congenital thrombophilia 
compared to women without thrombophilia. The authors 
concluded that hereditary thrombophilia may be an unrec-
ognized cause of RPL [61].
A meta-analysis, which included 31 population-based 
studies, showed that the magnitude of the correlation be-
tween congenital thrombophilia and fetal loss varies depend-
ing on the time of fetal loss and the type of thrombophilia. 
Only some forms of congenital thrombophilia are associated 
with fetal loss. In the first trimester, RPL was associated with 
the FVL G1691A gene mutation and prothrombin G20210A 
gene mutation, and late non-recurrent fetal loss was associ-
ated with the FVL G1691A gene mutation, the prothrombin 
G20210A gene mutation, and protein S deficiency. The FVL 
G1691A gene mutation was more strongly associated with 
late pregnancy loss than with early pregnancy loss, and in 
the case of exclusion of other potential causes of fetal loss. 
The MTHFR C677T gene mutation, protein C deficiency, 
and AT deficiency have not been significantly associated 
with fetal loss [62].
A large prospective case-control study (European Pro-
spective Cohort on Thrombophilia - EPCOT) enrolled 1384 
women (843 women with thrombophilia and 541 control 
women). The frequency of miscarriage (fetal loss before 28 
weeks of gestation) and stillbirth (fetal loss after 28 weeks 
of gestation) was assessed together and separately. The study 
found a statistically significant association of pregnancy 
loss in pregnant women with congenital thrombophilia, 
and stillbirth especially in women with combined defects or 
AT deficiency. Women with congenital thrombophilia (AT 
deficiency, protein C deficiency and protein S deficiency or 
FVL G1691A gene mutation) have a 3.6-fold higher risk of 
stillbirth and a 1.3-fold higher risk of miscarriage. Women 
with combined birth defects had the highest risk for still-
birth (14.3), compared with 5.2 for AT deficiency, 2.3 for 
protein C deficiency, 3.3 for protein S deficiency and 2.0 for 
the FVL G1691A gene mutation. The results obtained have 
important implications for treatment and provide a justifica-
tion for clinical trials of thromboprophylaxis in women with 
RPL [2, 56, 64].
In general, the data described above suggest a clear re-
lationship between congenital thrombophilia and negative 
pregnancy outcomes [65, 66]. However, heterogeneous small 
research groups, differences in study design, ethnicity, and 
geographical location may impact the results, limiting the 
statistical power of the research, the validity of the conclu-
sions and the practical importance of the phenomena stud-
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ied [10, 65]. For these reasons, some scientists believe that 
the evidence for the association of congenital thrombophilia 
with pregnancy loss should be interpreted with caution, as it 
is still weak and unconvincing, lacking the systematic inte-
gration of classification and co-factors [10, 65, 67, 68].
Women with combined thrombophilia, especially with 
congenital thrombophilia associated with acquired throm-
bophilia or two and more congenital thrombophilias, have 
the highest risk of early and late RPL [1, 7, 13, 56, 61, 69]. A 
meta-analysis and some case-control studies confirmed that 
the FVL G1691A gene mutation is a weak, but well-estab-
lished risk factor for unexplained RPL (two or more consec-
utive events) and for one or more late fetal losses with a risk 
increase of 2-7 times. A significantly increased risk (2.5-fold 
for early RPL and 2.3-fold for non-recurrent late fetal loss) 
was also determined in pregnant women with prothrombin 
G20210A gene mutation. A twofold increase in the risk of fe-
tal loss among pregnant women with AT deficiency, protein 
C deficiency, protein S deficiency, and FVL G1691A gene 
mutation has been reported in several studies [70].
A large population study evaluating 32.683 non-throm-
botic primigravida women revealed an association of the 
heterozygous FVL G1691A gene mutation and prothrombin 
G20210A gene mutation with a significant increased risk of 
miscarriage (3.2 and 2.4, respectively). The relationship was 
significant only in the group of women who had a miscar-
riage from the 10th week of gestation (3.5 and 2.6, respec-
tively) [51, 70, 71].
In recent years, the association of RPL with hypofibri-
nolytic gene polymorphisms (coagulation factor XIII V34L, 
PAI-1 4G / 4G, PAI-1 4G / 5G and ACE I / D gene muta-
tions) has become increasingly evident [43, 72, 73]. Homo-
zygous PAI-1 4G / 5G and MTHFR C677T gene mutations 
in women with RPL and the FVL G1691A, factor V H1299R, 
heterozygous ACE I / D gene mutations in both parents play 
a crucial role in RPL and should be considered risk factors. 
In addition, RPL is determined by thrombophilic gene mu-
tations in both parents (not just maternal gene mutations) 
[74]. However, a meta-analysis evaluating 11 studies with 
a total of 1545 women with RPL and 960 normal women, 
did not identify any associations of PAI-1 4G/5G gene muta-
tion with idiopathic RPL, including more than two or three 
recurrent miscarriages, in Caucasian and non-Caucasian 
population, but a high heterogeneity was identified in the 
included studies [69].
Therefore, in most cases, the evolution of pregnancy in 
pregnant women with congenital thrombophilia is devoid of 
events. However, there is an argument that women with any 
type of thromboembolic defect, especially with a combina-
tion of defects, have a higher prevalence of complications 
in pregnancy [37]. Although the results of published stud-
ies are contradictory, most comments suggest an association 
of RPL with FVL G1691A gene mutation and prothrombin 
G20210A gene mutation. These results vary in different 
populations, reflecting an interaction of several genetic and 
acquired risk factors [3, 51].
Although solid randomized data on this subject are miss-
ing, the analysis of existing results revealed that there is no 
relationship between congenital thrombophilia and RPL, 
or hereditary thrombophilia has a low impact on placenta-
mediated complications, probably explained by the study de-
sign differences, the relatively low prevalence of some forms 
of congenital thrombophilia and the small number of study 
participants, differences in inclusion and exclusion criteria, 
the inclusion of heterogeneous patient populations in dif-
ferent studies and the application of various definitions of 
complications that did not allow the researchers to identify 
a significant increase in the risk of RPL. The associations ob-
tained in some studies may be caused by the high frequency 
of these mutations in the population, which does not reflect 
the causal relationship [6].
Preeclampsia is an increasingly common, but poorly 
understood, multisystemic inflammatory syndrome of preg-
nancy, associated with abnormal placental development and 
homeostasis disorders leading to inadequate maternal-fetal 
circulation, caused by endothelial dysfunction, vasocon-
striction, placental ischemia, hypercoagulation with utero-
placental thrombosis [1, 11, 75]. 
Congenital thrombophilia may partially contribute to 
the development and severity of preeclampsia due to disor-
ders of the hemostatic system: hypercoagulability with vas-
culopathy and secondary thrombosis disrupt the perfusion 
of the intervillous space, contributing to the development of 
placental infarction, IUGR, PANPP, premature birth and in-
trauterine fetal death [2, 13, 56, 76].
Some case-control studies and prospective cohort stud-
ies (unicenter and multicenter) found the association of to-
tal and severe preeclampsia with thrombophilia (congenital 
and / or acquired). Thrombophilia exacerbates perinatal out-
comes in pregnant women with severe preeclampsia: the risk 
of premature birth (before 32 weeks of gestation), IUGR, and 
perinatal mortality are significantly higher [3, 77-79].
Data cumulated from several studies and meta-analyses 
found a significant association of FVL G1691A gene muta-
tion with total preeclampsia (twofold increased risk) and 
severe preeclampsia (threefold increased risk), prothrombin 
G20210A gene mutation with total, severe and mild pre-
eclampsia [3, 6, 77, 80-83]. Preeclampsia (total and severe) is 
the only complication in which a significant and consistent 
association with homozygosity of MTHFR C677T gene mu-
tation has been found. The presence of a very modest asso-
ciation with mild preeclampsia cannot be excluded, which is 
very difficult to detect even in significant groups of women 
[13, 20, 65, 77, 84].
A systematic literature review, published in 2002, found 
an increased risk of preeclampsia / eclampsia in pregnant 
women with heterozygous FVL G1691A gene mutation, het-
erozygous prothrombin G20210A gene mutation, homozy-
gous MTHFR C677T gene mutation, protein C deficiency, 
protein S deficiency or activated protein C resistance. Unfor-
tunately, the analysis included many small sample studies, 
which reduced the overall statistical power and no definitive 
conclusions could be drawn [51, 85].
Two recent extensive meta-analyses, published in 2014 
(111 studies with 15094 cases and 21633 controls) and in 
2015 (54 studies with 7398 cases and 11222 controls), thus 
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guaranteeing the statistical power of meta-analyses and ob-
taining more accurate estimates, revealed an association of 
MTHFR C677T gene polymorphism with an increased risk 
of preeclampsia, especially among Asian and Caucasian 
population [21, 51].
No relationship was found between the deficiency of 
natural anticoagulants (protein S, protein C and AT) with 
preeclampsia, as the number of subjects with such defects 
was too small to allow definitive conclusions to be drawn [3, 
65, 77], although some studies revealed a significant associa-
tion between protein C and preeclampsia [79].
However, a meta-analysis, published in 2003, and the 
most recent and well-designed systematic review and meta-
analysis of prospective cohort studies did not observe any 
consistent and significant effect of the FVL G1691A gene 
mutation and prothrombin G20210A gene mutation on the 
risk of preeclampsia, although a modest effect cannot be 
ruled out [14, 65, 86]. While studies published in 1996-2000 
demonstrated a significant association of the FVL G1691A 
gene mutation with preeclampsia, studies published in 2001-
2002 did not provide such convincing evidence, except for 
a small increased risk attributed to the FVL G1691A gene 
mutation for preeclampsia. At the same time, it must be ac-
knowledged that the meta-analysis cannot exclude the pos-
sibility of associating the FVL G1691A gene mutation with 
severe forms of preeclampsia [86].
Therefore, the association of preeclampsia with congeni-
tal thrombophilia is much more controversial. Currently, 
there is insufficient evidence to demonstrate the association 
of any form of congenital thrombophilia with preeclampsia. 
Several recent studies and meta-analyses suggest that there 
is an association between congenital thrombophilia and the 
development of severe preeclampsia but not mild one. Se-
vere preeclampsia is mainly associated with the FVL G1691A 
gene mutation, hyperhomocysteinemia, protein S and pro-
tein C deficiency, AT-III deficiency, prothrombin G20210A 
gene mutation, and MTHFR C677T gene mutation [1, 11].
Intrauterine growth restriction  is most commonly de-
fined as a fetal weight, estimated at the ultrasound exami-
nation, for gestational age less than the 10th percentile, and 
severe IUGR – an assessed fetal weight less than the 5th per-
centile [ 10, 11].
The association between congenital thrombophilia and 
IUGR or newborns small for gestational age (<2500 g) has 
not been consistently demonstrated in various studies and 
this relationship is highly controversial. The results vary 
from study to study, depending on the size of the study sam-
ple and the selection criteria used. However, a definitively 
determined causal relationship was not found, although an 
association was confirmed in women with severe IUGR, but 
not in cases with mild IUGR [1, 11, 12, 87, 88].
Some systematic literature analyses and meta-analyses 
noticed a significant association between the presence in 
mothers of the homozygous FVL G1691A gene mutation 
or the heterozygous prothrombin G20210A gene mutation 
with IUGR [8, 13, 17, 52, 90]. None of other congenital pro-
thrombotic defects have been associated with IUGR [3, 13].
A systematic literature review, published in 2002, found 
an increased risk of IUGR in pregnant women with hetero-
zygous prothrombin G20210A gene mutation, homozygous 
MTHFR C677T gene mutation, protein S deficiency or anti-
cardiolipin antibody IgG isotype. However, these analyses 
are not definitive due to the small sample size included in the 
studies and the large confidence interval, which reduced the 
impact of the findings [51, 85]. A prospective cohort study, 
published in 2015, confirmed that the presence of the ho-
mozygous MTHFR C677T gene mutation could increase the 
risk of developing IUGR [89].
Four studies – a family-based case-control study (pub-
lished in 2002) [88], a large prospective cohort study (pub-
lished in 2007) [91], a genetic study and a meta-analysis of 
prospective cohort studies (published in 2008) [81], a meta-
analysis of case-control studies and prospective cohort stud-
ies (published in 2009) [92] – contradict this association and 
did not reveal an increased risk of IUGR in pregnant women 
with polymorphisms of congenital thrombophilia.
Premature abruption of the normally positioned pla-
centa. In general, there is insufficient evidence to establish 
a link between congenital thrombophilia and PANPP, al-
though a potential association with thrombophilia is sug-
gested by a number of studies. The absence of a consistent 
association, demonstrated between any type of congenital 
thrombophilia and PANPP, is possibly caused by the low in-
cidence of these events [1, 11].
A systematic literature review, published in 2002, found 
an increased risk of PANPP in pregnant women with homo-
zygous and heterozygous FVL G1691A gene mutation, het-
erozygous prothrombin G20210A gene mutation, homocys-
teinemia and activated protein C resistance [85].
Some recent systematic literature reviews found a signifi-
cant risk of PANPP in pregnant women with heterozygous 
prothrombin G20210A gene mutation, followed by hetero-
zygous FVL G1691A gene mutation and hyperhomocys-
teinemia [3, 6, 13, 51]. A cohort study, published in 2015, 
confirmed that the presence of FVL G1691A gene mutation 
could increase the risk of PANPP [89].
However, these results were questioned in a meta-anal-
ysis of case-control studies, published in 2008, and a meta-
analysis of prospective cohort studies, published in 2010, 
which did not find any significant risk of premature abrup-
tion of the normally positioned placenta in women with 
FVL G1691A gene mutation or G20210A prothrombin gene 
mutation or MTHFR C677T gene mutation, except for some 
evidence of possible genetic causes [3, 14, 27].
Therefore, there is a small amount of robust evidence as-
sociated with negative pregnancy outcomes and congenital 
thrombophilia. The FVL G1691A gene mutation is associat-
ed with RPL and late pregnancy loss, prothrombin G20210A 
gene mutation is associated with RPL and late pregnancy 
loss, protein S deficiency is associated with late pregnancy 
loss. There is insufficient evidence to suggest an association 
of other forms of congenital thrombophilia with pregnancy 
complications. Due to the poor design quality of case-con-
trol studies and prospective cohort studies, there was often 
an increased relative risk of these complications, especially 
early RPL, fetal loss and preeclampsia, in women with con-
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genital thrombophilia. However, the magnitude of the asso-
ciation and the absolute risk remain very modest, suggesting 
that congenital thrombophilia is more of a contributing fac-
tor than a primary cause. The existence of a thrombophilic 
genetic defect does not exclude other risk factors, especially 
considering the multicausal etiology of obstetric complica-
tions in pregnancy. The literature analysis according to the 
severity of adverse pregnancy outcomes illustrates that the 
risk associated with congenital thrombophilia increases sig-
nificantly in pregnant women with severe obstetric compli-
cations (severe preeclampsia, eclampsia, PANPP, IUGR less 
than the 5th percentile or unexplained stillbirth) [3, 12, 89].
Conclusions
1. Prospective cross-sectional, case-control and cohort 
studies have shown that hereditary thrombophilia is more 
prevalent in the group of women with recurrent pregnancy 
loss, late miscarriage, early-onset preeclampsia, premature 
abruption of the normally positioned placenta, and intra-
uterine growth restriction.
2. There is convincing evidence that deficiency of natu-
ral anticoagulants (antithrombin, protein C, protein S) is a 
risk factor for late fetal loss. The factor V Leiden G1691A 
gene mutation and prothrombin G20210A gene mutation 
are associated with a double risk of recurrent early and un-
explained miscarriage as well as non-recurrent late fetal loss. 
The association of congenital thrombophilia with preeclamp-
sia is limited to the factor V Leiden G1691A gene mutation 
and more severe cases of preeclampsia. There is insufficient 
evidence to suggest an association of other forms of congeni-
tal thrombophilia with adverse pregnancy outcomes.
3. The risk associated with congenital thrombophilia in-
creases significantly in pregnant women with two or more 
forms of hereditary thrombophilia and in pregnant women 
with severe placenta-mediated pregnancy complications 
(severe preeclampsia, eclampsia, premature abruption of 
normally positioned placenta, intrauterine growth restric-
tion with weight below the 5th percentile or unexplained 
stillbirth).
4. Due to the poor design quality of case-control studies 
and prospective cohort studies, there has often been an in-
creased relative risk of pregnancy complications associated 
with congenital thrombophilia, especially early RPL, fetal 
loss and preeclampsia, but the extent of the association and 
the absolute risk remain very modest. Prospective, multi-
center studies are needed on large samples of patients, which 
would validate the role of thrombophilia in the development 
of obstetric diseases.
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